

BioLight Announces Issuance of Israeli Patent for the IOPTiMate™ Technology

TEL AVIV (February 1, 2014) - BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT; OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces the Israel patent office has issued patent covering the core of the IOPTiMate™ Technology for a non-penetrating laser assisted filtration surgery technology for treating glaucoma.

The patent, which is owned by IOPtima, one of BioLight's subsidiaries, will be in effect at least until November 2022.

The patent joins the registration in other territories worldwide, including the U.S, Japan, India, South Africa, and to other patents of the Company.

The registration is subject to customary fee payment.

About IOPtima

IOPtima, subsidiary of BioLight, develops and markets a non-penetrating CO2 laser assisted filtration surgery technology for treating glaucoma.

The IOPTiMate™ Technology has regulatory approvals for marketing products in Europe, China, Mexico and Israel.

About BioLight

BioLight Life Sciences Investments Ltd. invests in, manages and commercializes biomedical innovations grouped into "clusters" around defined medical conditions. The two current clusters are in ophthalmology via 100% ownership of XLVision Sciences, and in cancer diagnostics via a 39.6% controlling ownership of Micromedic Technologies (TASE: MCTC).